Advertisement

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




Aug
17
Today In Oncology
Darovasertib Plus Crizotinib May Set New First-Line Standard in HLA-A2–Negative Metastatic Uveal Melanoma
AASLD Publishes Landmark North American Framework to Advance Treatment Decisions for HCC
AI Model Predicts TP53 Status Tumor Type and Survival From Routine HE Slides
Adding Irinotecan to Preoperative Chemoradiotherapy Does Not Improve Outcomes in Locally Advanced Rectal Cancer
Early Intravesical Pirarubicin Improves Relapse-Free Survival in Upper Tract Urothelial Carcinoma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo